A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis
收藏DataCite Commons2025-05-30 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007645/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™)
as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with
subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had
not previously received MS disease-modifying therapies. Participants had monthly laboratory
tests and comprehensive testing every 3 months.
提供机构：
Vivli
创建时间：
2022-02-02
